Exceptional Clinical Circumstances Request: Armour Thyroid
Patient SB NHS No 9999999999 DoB 05.05.9999
Thank you for your request for funding armour thyroid for the above patient to treat acquired hypothyroidism; this was considered by the Exceptional Clinical Circumstances panel at their recent meeting.
The panel considered the information provided in the proforma and also the information provided by the patient. They also took into consideration the most recent UKMI review dated November 11, which states the following:
“A combination of levothyroxine and liothyronine, in both non- and physiological proportions, has not consistently been shown to be more beneficial than levothyroxine alone with respect to cognitive function, social functioning and wellbeing. Use of dried thyroid hormone extracts, such as Armour® Thyroid, is therefore not recommended. The variation in hormonal content and large amounts of liothyronine may lead to increased serum concentrations of T3 and subsequent thyrotoxic symptoms, such as palpitations and tremor”
The panel also noted:
•Armour Thyroid is not a not a licensed product in the UK, and is only available as an unlicensed special.
•The British Thyroid Association Executive Committee does not recommend the use of combined thyroxine (T4) and tri-iodothyronine (T3).
•There is insufficient clinical evidence of effectiveness to support the use of Armour thyroid, and potential side effects, quality and cost concerns.
In view of all of the above the panel were unable to support the request for Armour Thyroid.
Head/Strategic Lead for Medicines Management
Essex Commissioning Support on behalf of NEE CCG
cc:Kathy Bardell, IFR Coordinator – Exceptional Clinical Cases & Individual Funding
Requests, NEE CCG